Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.77 |
| ▸ | HTT | P42858 | 2/20 | 0.77 |
| ▸ | THRB | P10828 | 1/20 | 0.77 |
| ▸ | MAPT | P10636 | 1/20 | 0.77 |
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | TSHR | P16473 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | CES2 | O00748 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 6/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9646500 | 1.00 | MEN1 (0.77) | MEN1KMT2AHTTTHRBMAPT | |
| SCHEMBL8956073 | 1.00 | MEN1 (0.77) | MEN1KMT2AHTTTHRBMAPT | |
| SCHEMBL2527727 | 1.00 | MEN1 (0.77) | MEN1KMT2AHTTTHRBMAPT | |
| SCHEMBL314263 | 1.00 | MEN1 (0.77) | MEN1KMT2AHTTTHRBMAPT | |
| SCHEMBL23014943 | 1.00 | MEN1 (0.77) | MEN1KMT2AHTTTHRBMAPT | |
| SCHEMBL23014835 | 1.00 | MEN1 (0.77) | MEN1KMT2AHTTTHRBMAPT | |
| SCHEMBL139902 | 1.00 | MEN1 (0.77) | MEN1KMT2AHTTTHRBMAPT | |
| SCHEMBL24304662 | 1.00 | MEN1 (0.77) | MEN1KMT2AHTTTHRBMAPT | |
| SCHEMBL16815923 | 1.00 | MEN1 (0.77) | MEN1KMT2AHTTTHRBMAPT | |
| SCHEMBL427999 | 1.00 | MEN1 (0.77) | MEN1KMT2AHTTTHRBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461135-B2 | Boron-containing small molecules as anti-inflammatory agents | ANACOR PHARMACEUTICALS, INC. (US) | 2013-06-11 | — | — | US | claimed |
| US-8039450-B2 | Boron-containing small molecules as anti-inflammatory agents | ANACOR PHARMACEUTICALS, INC. (US) | 2011-10-18 | — | — | US | claimed |
| US-12034122-B2 | Electrolytic solution for lithium-ion secondary battery and lithium-ion secondary battery | MURATA MANUFACTURING CO., LTD. (JP) | 2024-07-09 | — | — | US | disclosed |
| CN-112074983-B | Electrolyte for lithium ion secondary battery and lithium ion secondary battery | 株式会社村田制作所 | 2024-06-04 | — | — | CN | disclosed |
| EP-4374877-A2 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR AND PHOSPHORUS ADSORBENT FOR USE IN THE PREVENTION, TREATMENT OR SUPPRESSION OF CHRONIC KIDNEY DISEASE, ARTERIOSCLEROSIS ASSOCIATED WITH VASCULAR CALCIFICATION, OR ECTOPIC CALCIFICATION. | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-29 | — | — | EP | disclosed |
| EP-3928779-B1 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR AND PHOSPHORUS ADSORBENT FOR USE IN THE PREVENTION, TREATMENT OR SUPPRESSION OF CHRONIC KIDNEY DISEASE, ARTERIOSCLEROSIS ASSOCIATED WITH VASCULAR CALCIFICATION, OR ECTOPIC CALCIFICATION. | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2024-03-06 | — | — | EP | disclosed |
| CN-112638477-B | Pyrrolo [2,3-B ] pyridine derivatives as inhibitors of influenza virus replication | 共晶制药公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-110637022-B | Pyrrolopyrimidine derivatives as inhibitors of influenza virus replication | 共晶制药公司 | 2022-09-16 | — | — | CN | disclosed |
| EP-3928779-A1 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR AND PHOSPHORUS ADSORBENT FOR USE IN THE PREVENTION, TREATMENT OR SUPPRESSION OF CHRONIC KIDNEY DISEASE, ARTERIOSCLEROSIS ASSOCIATED WITH VASCULAR CALCIFICATION, OR ECTOPIC CALCIFICATION. | Chugai Seiyaku Kabushiki Kaisha (JP) | 2021-12-29 | — | — | EP | disclosed |
| EP-3192511-B1 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2021-07-14 | — | — | EP | disclosed |
| US-11014941-B2 | Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication | COCRYSTAL PHARMA, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-5053514-A | Side effect reduction; carbostyril derivatives | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1991-10-01 | — | — | US | disclosed |
| EP-0239129-B1 | HYDROQUINOLINE COMPOUNDS, COMPOSITIONS CONTAINING SAME AND PROCESSES FOR PREPARING SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-09-25 | — | — | EP | disclosed |
| US-5037827-A | Useful for treatment of disease caused by platelet activating factory | EISAI CO., LTD. (JP) | 1991-08-06 | — | — | US | disclosed |
| EP-0411150-A1 | INDOLE DERIVATIVES, PREPARATION THEREOF, AND DRUG FOR PREVENTING AND TREATING NEPHRITIS CONTAINING SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-02-06 | — | — | EP | disclosed |
| US-4963566-A | ANTIULCER AGENT | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-10-16 | — | — | US | disclosed |
| EP-0353474-A2 | Glycerin derivative and its pharmacological use | Eisai Co., Ltd. (JP) | 1990-02-07 | — | — | EP | disclosed |
| CN-1039414-A | Glycerol derivatives and pharmaceutical use thereof | EISAI CO LTD (JP) | 1990-02-07 | — | — | CN | disclosed |
| US-4743383-A | ORGANOPHILIC CLAY, PREVENTION OF FLUID LOSS | PHILLIPS PETROLEUM COMPANY (US) | 1988-05-10 | — | — | US | disclosed |
| EP-0239129-A2 | Hydroquinoline compounds, compositions containing same and processes for preparing same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-09-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11014941-B2 | Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication | ITPA, POLR2H, POLR2E | MEN1 4650/4885KMT2A 2703/4885HTT 3679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.